Communications Biology (Jul 2022)
A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron
- Ryota Maeda,
- Junso Fujita,
- Yoshinobu Konishi,
- Yasuhiro Kazuma,
- Hiroyuki Yamazaki,
- Itsuki Anzai,
- Tokiko Watanabe,
- Keishi Yamaguchi,
- Kazuki Kasai,
- Kayoko Nagata,
- Yutaro Yamaoka,
- Kei Miyakawa,
- Akihide Ryo,
- Kotaro Shirakawa,
- Kei Sato,
- Fumiaki Makino,
- Yoshiharu Matsuura,
- Tsuyoshi Inoue,
- Akihiro Imura,
- Keiichi Namba,
- Akifumi Takaori-Kondo
Affiliations
- Ryota Maeda
- Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University
- Junso Fujita
- Graduate School of Frontier Biosciences, Osaka University
- Yoshinobu Konishi
- Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University
- Yasuhiro Kazuma
- Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University
- Hiroyuki Yamazaki
- COGNANO Inc.
- Itsuki Anzai
- Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University
- Tokiko Watanabe
- Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University
- Keishi Yamaguchi
- Graduate School of Pharmaceutical Sciences, Osaka University
- Kazuki Kasai
- COGNANO Inc.
- Kayoko Nagata
- Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University
- Yutaro Yamaoka
- Department of Microbiology and Molecular Biodefense Research, Yokohama City University Graduate School of Medicine
- Kei Miyakawa
- Department of Microbiology and Molecular Biodefense Research, Yokohama City University Graduate School of Medicine
- Akihide Ryo
- Department of Microbiology and Molecular Biodefense Research, Yokohama City University Graduate School of Medicine
- Kotaro Shirakawa
- Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University
- Kei Sato
- Division of System Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo
- Fumiaki Makino
- Graduate School of Frontier Biosciences, Osaka University
- Yoshiharu Matsuura
- Centre for Infectious Disease Education and Research, Osaka University
- Tsuyoshi Inoue
- Graduate School of Pharmaceutical Sciences, Osaka University
- Akihiro Imura
- COGNANO Inc.
- Keiichi Namba
- Graduate School of Frontier Biosciences, Osaka University
- Akifumi Takaori-Kondo
- Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University
- DOI
- https://doi.org/10.1038/s42003-022-03630-3
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 16
Abstract
A panel of nanobodies are presented that can detect the spike proteins of five SARS-CoV-2 variants of concern and structural analyses show that one clone targets conserved epitopes on the receptor-binding domain and contacts the N-terminal domain.